Theodore S. Hong, MD of Massachusetts General Hospital outlines a Phase II Study of Folfirinox followed my Individualized Radiation Therapy with Borderline Resectable Pancreatic Cancer at ASCO GI 2017.
Phase II Study Folfirinox followed my Individualized Radiation Therapy with Borderline Resectable Pancreatic Cancer
